Question 1

A 29-year-old man with schizophrenia is switched from risperidone to aripiprazole because of elevated prolactin causing gynecomastia. Two weeks later, he reports feeling "jittery inside" and unable to sit through meals. His psychosis remains well-controlled. What is the most likely explanation?

Accepted Answer

Akathisia affects approximately 10-25% of patients on aripiprazole and is characterized by a subjective feeling of inner restlessness and an inability to sit still. It typically emerges within the first days to weeks of starting aripiprazole. This is distinct from psychotic agitation (his psychosis is well-controlled) and from anxiety (though the two are frequently confused). The timing, two weeks after initiation, and the description ("jittery inside," unable to sit through meals) are classic. Management options include dose reduction, adding propranolol, or adding a benzodiazepine short-term.

Question 2

A 45-year-old woman with treatment-resistant depression has achieved partial response on sertraline 200mg (PHQ-9 improved from 22 to 14). You add aripiprazole. What starting dose is most appropriate for this indication, and why?

Accepted Answer

Aripiprazole for depression augmentation is dosed at 2-5mg, dramatically lower than the 10-30mg range used for psychosis. This is because the goal is not D2 receptor modulation for psychotic symptoms but rather the combined effect of mild dopaminergic modulation, 5-HT1A partial agonism, and 5-HT2A antagonism to enhance the SSRI response. Higher doses increase akathisia risk without proportionally increasing antidepressant benefit. The dose range for augmentation and the dose range for psychosis are essentially different medications: same molecule, different clinical application.

Question 3

A patient on risperidone 4mg has developed amenorrhea and a prolactin level of 85 ng/mL (normal <25). She is stable psychiatrically and does not want to switch antipsychotics. A colleague suggests adding aripiprazole to lower the prolactin. What pharmacological principle makes this strategy work?

Accepted Answer

Aripiprazole's partial agonism at D2 receptors in the tuberoinfundibular pathway generates enough dopamine signal to restore tonic inhibition of prolactin release. This works even in the presence of risperidone because aripiprazole can compete for receptor binding and provide its partial signal. This is one of the most elegant clinical applications of the partial agonist concept: using aripiprazole not as a primary treatment but as an antidote to another antipsychotic's side effect. Typical doses for this purpose are low (2-5mg).

Aripiprazole

Side Effects Worth Knowing

Akathisia: inner restlessness, inability to sit still, pacing

Insomnia and Activation: restlessness, agitation, difficulty sleeping

Weight and Metabolic Effects: generally favorable compared to other antipsychotics

Prolactin Effects: can lower prolactin, sometimes below baseline

Compulsive Behaviors: gambling, shopping, binge eating, hypersexuality

Serotonin Syndrome Risk: when combined with other serotonergic agents

See This Medication in Action

References & Further Reading